Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB) Change in Acquisitions & Divestments (2023 - 2025)

Historic Change in Acquisitions & Divestments for Nuvation Bio (NUVB) over the last 3 years, with Q3 2025 value amounting to $78.5 million.

  • Nuvation Bio's Change in Acquisitions & Divestments fell 3167.2% to $78.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $414.1 million, marking a year-over-year decrease of 2444.48%. This contributed to the annual value of $450.1 million for FY2024, which is 3681.72% down from last year.
  • As of Q3 2025, Nuvation Bio's Change in Acquisitions & Divestments stood at $78.5 million, which was down 3167.2% from $136.7 million recorded in Q2 2025.
  • In the past 5 years, Nuvation Bio's Change in Acquisitions & Divestments registered a high of $244.2 million during Q2 2023, and its lowest value of $78.5 million during Q3 2025.
  • In the last 3 years, Nuvation Bio's Change in Acquisitions & Divestments had a median value of $115.3 million in 2024 and averaged $135.7 million.
  • Its Change in Acquisitions & Divestments has fluctuated over the past 5 years, first tumbled by 5387.96% in 2024, then skyrocketed by 1860.29% in 2025.
  • Nuvation Bio's Change in Acquisitions & Divestments (Quarter) stood at $181.9 million in 2023, then tumbled by 53.88% to $83.9 million in 2024, then dropped by 6.4% to $78.5 million in 2025.
  • Its Change in Acquisitions & Divestments stands at $78.5 million for Q3 2025, versus $136.7 million for Q2 2025 and $115.0 million for Q1 2025.